Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Continues Cannabinoid Analysis Required In FY2021 Budget

May 19 2021

• By Eileen Francis

Related Content

FDA Action Items For CBD Policy? The List Is Short Due To 'Critical' Data Gaps

Jan 20 2020

Tests Show CBD Levels In Some Supplements Don't Match Labeling

Dec 05 2019

$2m For CBD Policy In FDA Budget, But No Directive On Setting Safe Level

Dec 19 2019

US House Appropriators Request CBD Enforcement As They Ante Up $5M For FDA's Rule Development

Jul 10 2020

Funding For US FDA Work On Cannabinoids Regulatory Pathway Drives Progress Only So Far

Apr 08 2021

US Senate Appetite For Lawful Use Of Cannabinoids Includes Food On Top Of Supplements

May 19 2021

Legislating Hemp As Dietary Ingredient: Wrapping US Market In A Bow, Or Tying DSHEA In Knots?

Mar 09 2021

Additional Topics

International United States US States Cannabidiol CBD FDA Legislation Commercial Compliance Dietary Supplements Enforcement Ingredients Manufacturing Policy Politics Regulation Consumer

More from Cannabis/CBD

More from Ingredients & Safety

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window